IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
25 juil. 2024 16h05 HE
|
IO Biotech
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech to Present at Jefferies Global Healthcare Conference
23 mai 2024 08h30 HE
|
IO Biotech
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
14 mai 2024 07h55 HE
|
IO Biotech
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine,...
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 16h30 HE
|
IO Biotech
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
15 avr. 2024 08h30 HE
|
IO Biotech
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
09 avr. 2024 12h00 HE
|
IO Biotech
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
05 avr. 2024 08h30 HE
|
IO Biotech
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
06 mars 2024 16h11 HE
|
IO Biotech
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
05 mars 2024 16h40 HE
|
IO Biotech
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
IO Biotech to Present at 44th Annual Cowen Health Care Conference
26 févr. 2024 16h05 HE
|
IO Biotech
IO Biotech to Present at 44th Annual Cowen Health Care Conference